Health AI Central
Share:
Peer-Reviewed Publication
World J Diabetes2025;16(2):98552.February 15, 2025Journal Article

Efficacy of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort.

Di-Fei Lu1, Rui Zheng2, Ang Li1, Jun-Qing Zhang3
1Department of Endocrinology, Peking University First Hospital, Beijing 100034, China.
2iHealth Labs China Co., Ltd., Beijing 100034, China.
3Department of Endocrinology, Peking University First Hospital, Beijing 100034, China. junqing.zhang@pkufh.com.
PubMed PMC DOI PDF

Abstract

BACKGROUND: With accumulating evidence showing a benefit in the renal and cardiovascular systems, diabetes guidelines recommend that patients with diabetes and chronic kidney disease (CKD) be treated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) and/or glucagon like peptide-1 receptor agonists (GLP-1RAs) for renal protection. The real-world efficacy of the two medications on the urinary a…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.